All data are based on the daily closing price as of September 6, 2024
s
Sunmax Biotechnology
4728.TWO
8.72 USD
0.14
+1.63%
Overview
Last close
8.72 usd
Market cap
474.81M usd
52 week high
10.71 usd
52 week low
4.61 usd
Target price
N/A usd
Valuation
P/E
21.319
Forward P/E
N/A
Price/Sales
8.6038
Price/Book Value
12.7061
Enterprise Value
441.38M usd
EV/Revenue
8.0337
EV/EBITDA
13.1545
Key financials
Revenue TTM
54.94M usd
Gross Profit TTM
27.93M usd
EBITDA TTM
31.03M usd
Earnings per Share
0.41 usd
Dividend
0.34 usd
Total assets
2.39B usd
Net debt
N/A usd
About
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.